Sino Biopharmaceutical (HK:1177) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sino Biopharmaceutical has received approval to submit a marketing application for its innovative drug combination, Benmelstobart Injection and Anlotinib Hydrochloride Capsules, aimed at treating the ultra-rare alveolar soft part sarcoma (ASPS). With a high tendency for metastasis and limited treatment options, this new combination therapy offers hope for improved outcomes in ASPS patients. This development marks a significant step for Sino Biopharmaceutical in expanding its portfolio of effective cancer treatments.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.